| Date Filed | Type | Description |
| 04/08/2010 |
8-K
| Quarterly results |
| 03/09/2010 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/02/2010 |
8-K
| Other Events, Financial Statements and Exhibits |
| 02/22/2010 |
8-K
| Other Events, Financial Statements and Exhibits |
| 02/18/2010 |
8-K
| Form 8-K - Current report |
| 01/25/2010 |
8-K
| Other Events, Financial Statements and Exhibits |
| 01/08/2010 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 12/31/2009 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/16/2009 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/24/2009 |
8-K
| Form 8-K - Current report |
| 10/13/2009 |
8-K
| Other Events, Financial Statements and Exhibits |
| 09/09/2009 |
8-K
| Form 8-K - Current report |
| 09/02/2009 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/14/2009 |
8-K
| Conference call transcript |
| 05/15/2009 |
8-K
| Quarterly results, Conference call transcript |
| 04/27/2009 |
8-K
| Form 8-K -- Current report |
| 04/17/2009 |
8-K
| Form 8-K -- Current report |
| 04/14/2009 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/13/2009 |
8-K
| Quarterly results, Conference call transcript |
| 02/18/2009 |
8-K
| Form 8-K -- Current report |
| 01/07/2009 |
8-K
| Form 8-K -- Current report |
| 12/16/2008 |
8-K
| Form 8-K -- Current report |
| 12/03/2008 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Vion Pharmaceuticals Adds Tanya Lewis to Senior Management Team NEW HAVEN, CT, December 2, 2008 — VION PHARMACEUTICALS, INC. today announced that Tanya Lewis had joined its senior management team as Vice President, Regulatory and Quality Affairs. Alan Kessman, Chief Executive Officer, said, ”We are extremely pleased to have Tanya Lewis joining Vion to head our regulatory and quality affairs efforts. She has extensive experience in these areas, and with a particular focus on oncology drugs, having played a significant role on the regulatory approvals for Velcade Ò .” He concluded, “She will lead our interactions with the U.S. Food and Drug Administration, starting with our effort to file a New Drug Application for laromustine with the FDA in early 2009.” Ms. Lewis commented, “I am excited about joining Vion and looking forward to working with the rest of the senior management team to pursue regulatory approval for laromustine in the United States.” Ms. Lewis has been advising Vion on re..." |
|
| 11/10/2008 |
8-K
| Form 8-K -- Current report |
| 10/17/2008 |
8-K
| Form 8-K -- Current report |
| 09/23/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/21/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/18/2008 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 08/08/2008 |
8-K
| Conference call transcript |
| 07/18/2008 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers |
| 06/30/2008 |
8-K
| Other Events |
| 06/25/2008 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ... |
| 06/17/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/04/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
|